The value of Bristol’s work came to the fore when the EU granted a license for the new Bexsero vaccine in 2013. The Joint Committee on Vaccination and Immunisation (JCVI), which advises the government ...

The programme will deploy GSK's meningococcal vaccine Bexsero (4CMenB), which was recommended by the UK's Joint Committee for Vaccination and Immunisation (JCVI) in 2023 in populations at high ...

GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...